ADMA Biologics (ADMA) trades at $11.17, and the balance of evidence now leans positive for the next 2–6 weeks, a reversal from the bearish reading of October 16, 2026. The stock has moved above its 40-week average, leads both the S&P 500 and the healthcare sector over 50 days, and sits just under the $11.37 level that would confirm a breakout. Conviction is high, with earnings due November 4.
Why it matters
The only recent news item is not an ADMA event. On September 22, 2026 Kedrion Biopharma announced that the FDA had granted Orphan Drug Designation to its immunoglobulin product QIVIGY for Stiff Person Syndrome, PR Newswire reported. It is a competitor's regulatory step in a rare-disease niche, a month old, and it does not explain the recent move in ADMA. The stock's advance has no identifiable headline behind it, and that matters for how much weight it can carry.
The move itself is modest over the last week and larger over the last month. ADMA is up 1.5% over five days, against a 0.4% fall for the S&P 500 and a 0.6% gain for the healthcare sector (XLV). The stock therefore beat its sector by about 0.9 percentage points, and the market was no help. Over one month ADMA is up 10.4%, against 0.6% for the S&P 500 and 5.1% for XLV. Over 50 days it leads the S&P 500 by 12.1 points and XLV by 7.4 points. This is mostly the stock's own strength, with the sector contributing a smaller part.
The longer record is less flattering. ADMA is still down 38.8% year to date while the S&P 500 is up 13.0% and XLV is up 16.3%. Against the S&P 500 it still trails by 5.4 points over 200 days. The shares are 45.2% below their 52-week high of $20.38 and 47.0% above the low of $7.60. The recent rally is a recovery inside a much larger drawdown, not a return to old highs.
No articles making a case for or against ADMA were available for this report, so the debate has to be taken from the numbers. Four analysts cover the stock and none carries a consensus rating. Their price targets run from $12 to $21 with a mean of $17, which puts the shares 34.3% below the mean. Even the lowest target is above today's price. That spread is wide, and it shows how far the analysts' view of the company's earning power sits from what the market is paying for a $2.5 billion biotech.
What the evidence says
On the long term, the thesis has gone from broken to repaired but unproven. On October 16, 2026 the earlier report called the stance bearish with low conviction, because price was below its 40-week average and the daily trend was only a pullback within a downtrend. That reading rested on a weekly close above $11.31, the 200-day average at the time, as the point that would change it. Since then the 200-day average has eased to $11.02, and price has moved above it and above the 40-week average. The weekly trend is up, and the stock is in the early phase of a recovery from a deep decline, not in a mature uptrend.
For the next 2–6 weeks the evidence leans positive, with high conviction of 3 of 4 points. The daily trend runs with the weekly uptrend, and ADMA leads both the S&P 500 and XLV over 50 days. That agreement is why the stance changed from the earlier report. Trend and relative strength both point the same way now, and in October 16 they did not.
The strongest case against it is that the breakout has not happened. The stock closed at $11.23 on October 20, 2026, and it now trades 0.5% below that peak, still under the $11.37 resistance. The 14-day RSI is 67.5, close to overbought territory, and volume in the session so far is far below its 20-day average, though the day is young. Earnings on November 4 can overwhelm any chart. These points are why conviction is not at the maximum, but they do not outweigh a trend and relative-strength picture that agree.
Levels that matter
The structure holds above $11.02, the 200-day average. That is the first place a crack would show, and the price is only slightly above it. Below it the trend ends at $9.93, the 50-day average, close to the $10.00 round number and the next support zones at $9.26 and $8.20. Those levels matter because they are where buyers have defended the stock before, and the 200-day and 50-day averages are the lines most holders of the stock watch.
The breakout level is a daily close above $11.37 on volume above its 20-day average. From there, resistance sits at $12.00 and $13.00, and the 52-week high of $20.38 is the target in the math. The stop is $10.93, which is the 200-day average at $11.02 minus a quarter of the 14-day ATR of $0.34. Against that stop the reward-to-risk to $20.38 is 20.5 to 1, well past the 3 to 1 that makes a breakout worth the risk. That ratio is large mainly because the stop is so tight, and the target is a long way off. A close below $10.93 would mean the breakout failed.
What would change the picture
A weekly close below $9.93, the 50-day average, would change the picture, because it would end the weekly trend that the current reading rests on. The non-price fact that could do it is the earnings report on November 4: results or guidance that disappoint, in a stock that has risen without a news catalyst, could take the price through the $11.02 and $10.00 levels on the way down.
What to watch
- Earnings, November 4, 2026: quarterly revenue is the number that matters, since the rally has been built on price strength and not on news.
- Sector: XLV is up 5.1% over a month and has been outpacing the market. A turn in healthcare would move ADMA before any company news does, and the stock's 7.4-point lead over XLV over 50 days would be tested.
- Volume at $11.37: a close above it on volume above the 20-day average is the confirmation the math depends on.
- Valuation: the $17 mean analyst target sits 34.3% above the price, with targets from $12 to $21 and no consensus rating from the four analysts.